Navigation Links
Avanir Pharmaceuticals Announces Results for Phase II PRIME Study
Date:12/10/2013

ALISO VIEJO, Calif., Dec. 10, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that PRIME, its phase II clinical trial of the investigational drug AVP-923 (dextromethorphan / quinidine) for the treatment of central neuropathic pain in patients with multiple sclerosis did not meet the primary efficacy endpoint.

(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)

In the PRIME study, AVP-923 treated patients experienced levels of pain reduction commensurate with those observed in similar studies and the improvement in pain scores from baseline reached statistical significance; however, there was no difference between the treatment arms and placebo.  Avanir believes that a higher than expected placebo response negatively impacted the study results.  AVP-923 was generally safe and well tolerated.

Avanir plans to review the detailed data from the PRIME study in conjunction with previously generated data in diabetic peripheral neuropathic pain to determine next steps for the development of AVP-923 in neuropathic pain.

About the PRIME Study
The objectives of the PRIME (Pain Research In Multiple sclErosis) study were to evaluate the safety, tolerability, and efficacy of AVP-923 for the treatment of central neuropathic pain in patients with multiple sclerosis. The trial was a multicenter, randomized, double-blind, placebo-controlled, 4-arm parallel group study that enrolled 209 patients. Eligible patients received one of three dose levels of AVP-923 containing either 45mg DM/10 mg Q, 30mg DM/10mg Q, 20mg DM/10mg Q or placebo, daily for 12 weeks. The primary efficacy endpoint was measured based on the Numeric Pain Rating Scale (PRS) as recorded in patient diaries. Primary analysis of this endpoint correlated pain
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Preliminary Financial Results, Quarterly Reports and Upcoming Conference Schedules - Research Report on Avanir, BioScrip, Chemed, Foundation Medicine, and Antares
2. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2013 Year End Financial Information
3. Avanir Pharmaceuticals to Host Investor Day on October 29, 2013
4. Avanir Pharmaceuticals Announces Enrollment of First Patient in Study of AVP-923 for the Treatment of Levodopa Induced Dyskinesia in Parkinsons Disease
5. Avanir Pharmaceuticals Announces Publication of AVP-825 Pharmacokinetic Data in Journal "Headache"
6. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
7. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
8. Avanir Pharmaceuticals Announces Publication of PRISM Pseudobulbar Affect Registry Findings
9. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
10. Avanir Pharmaceuticals Announces Diabetes Co-Promotion Agreement with Merck
11. Avanir Pharmaceuticals Reports Fiscal 2013 Third Quarter Financial and Business Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... April 1, 2015 Jintian Pharmaceutical Group Limited ... that Mr. Jin Dongtao, chairman and executive director purchased ... 2% of the existing entire issued share capital of ... share with the total amount of approximately HK$113 million. ... shareholding will increase from 45.17% to 47.17%. ...
(Date:4/1/2015)... DUBLIN , Mar. 30, 2015 Research and ... addition of the "An Introduction to the Medical ... This seminar provides a detailed introduction to the European ... which products are covered, the involvement of Notified Bodies, ... must do. It will also cover the documentation necessary ...
(Date:4/1/2015)... , April 1, 2015  Philips Respironics, a division ... PHIA), today announced the Pico nasal mask is ... for the treatment of obstructive sleep apnea (OSA). Designed to ... traditional continuous positive air pressure (CPAP) mask available on the ... sleep and respiratory solutions, will be on display at ...
Breaking Medicine Technology:Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 2Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 3Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 4Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 5An Introduction to the Medical Device Directives Training: London, UK - 13th, 14th, 15th of May 2015 2Philips Pico CPAP Nasal Mask Now Available in the United States 2Philips Pico CPAP Nasal Mask Now Available in the United States 3
... Feb. 14, 2011 Thoratec Corporation (Nasdaq: THOR ... to save, support and restore failing hearts, announced today that ... to $100 million of the company,s shares of common stock ... confidence in the long-term strength of the company, as well ...
... 14, 2011 Mesa Laboratories, Inc. (Nasdaq: ... has declared a regular quarterly cash dividend of 12 ... 15, 2011 to shareholders of record at the close ... Laboratories develops, acquires, manufactures and markets electronic instruments and ...
Cached Medicine Technology:Thoratec Corporation Authorizes $100 Million Share Repurchase Program 2Thoratec Corporation Authorizes $100 Million Share Repurchase Program 3
(Date:4/1/2015)... 01, 2015 IQ Formulations , one ... nutritional supplement companies in the U.S., today is commending GNC ... quality control standards for its herbal supplements.* GNC vowed that ... to ensure the accuracy of labeling on its products. ... IQ Formulations CEO Jay Cohen said: , ...
(Date:4/1/2015)... PA (PRWEB) April 01, 2015 Health ... company and a subsidiary of West Corporation, today launched ... at http://blog.healthadvocate.com and through the Health Advocate ... healthcare consumers get, and stay, healthy. , “We’re pleased ... available to the public,” said Martin Rosen, Executive Vice ...
(Date:4/1/2015)... WI (PRWEB) April 01, 2015 When ... dryness occur, waiting days or weeks for an appointment ... Historically same and next day appointments haven’t been possible ... area, Forefront Dermatology’s offices have noticed demand for this ... , “We realize how important relief or answers to ...
(Date:4/1/2015)... 01, 2015 Senior Helpers of Central ... Care Provider of Choice Award by Home Care Pulse. The ... is given to home care providers who receive the highest ... for quality in home care. This recognition reassures you that ... will provide you with quality, trustworthy in home care. , ...
(Date:4/1/2015)... 01, 2015 The 2015 Deep ... is a professional and in-depth study on the ... Market with a focus on the Chinese ... market research are Pfizer, Lek Pharmaceuticals D.D., Dr ... India Private Limited, Cadila Healthcare Limited, Sandoz Inc, ...
Breaking Medicine News(10 mins):Health News:IQ Formulations Applauds GNC for Enhancing Its Testing and Quality Control Processes for Herbal Supplements 2Health News:Health Advocate Launches New Health and Wellness Blog 2Health News:Dermatology Associates of Wisconsin and Forefront Dermatology Answers Patients' Needs With Unmatched Availability In Sheboygan and Sheboygan Falls 2Health News:Senior Helpers of Central Texas Awarded Prestigious 2015 Senior Home Care Provider of Choice Award from Home Care Pulse 2Health News:Atorvastatin Calcium Industry International & China Market Analysis 2015-2020 2Health News:Atorvastatin Calcium Industry International & China Market Analysis 2015-2020 3
... arterial oxygenation deficiency occurs due to intra-pulmonary vascular ... disease. HPS occurs in 15-20% of patients with ... Recent studies support that the presence of HPS ... with decompensated liver disease. , One of ...
... parents would hotly deny favouring one child over another but ... matter. , Biologists studying a unique species of beetle that ... instinctively favour the oldest offspring. , The University of Manchester ... findings of studies carried out on human families but is ...
... New Year Favorite, and ,Have Fun Helping It ... ... terror attack?,Pandemic? Recession? Killer bees? No! Only positive predictions, please.,That,s the attitude ... made its debut last month., *(PHOTO 72dpi: Send2Press.com/mediaboom/07-1115-DSamson_72dpi.jpg), *(Photo Caption: ...
... Dec. 19 K2 Sports announced today the January,2008 ... care products developed,and tested to satisfy the extraordinary demands ... altitudes. Answering the call from,medical professionals concerned with the ... will feature three high performance,products: the K2 Endurance Sunblock ...
... as a lender under the line of ... credit., ... negotiated an increase in its secured revolving,line of credit with LaSalle Bank National ... the line of credit has increased from $50 million to $80,million. The line ...
... Dec. 18 /PRNewswire-FirstCall/ - Aspreva Pharmaceuticals,Corporation (NASDAQ: ... British,Columbia Supreme Court has issued a final order ... (SWX: GALN), through a wholly-owned,Canadian subsidiary, will acquire ... US$26.00 per share in cash., The transaction, ...
Cached Medicine News:Health News:Who is the arch-criminal in the development of hepatopulmonary syndrome? 2Health News:Parents show bias in sibling rivalry, says study 2Health News:Six Positive Predictions for 2008, from SuperLife World Service 2Health News:K2 Sports Announces New Endurance Suncare Product Rollout for 2008 2Health News:K2 Sports Announces New Endurance Suncare Product Rollout for 2008 3Health News:Grubb & Ellis Healthcare REIT Increases Line of Credit With LaSalle Bank to $80 Million 2Health News:Grubb & Ellis Healthcare REIT Increases Line of Credit With LaSalle Bank to $80 Million 3Health News:Aspreva receives final court approval for acquisition by Galenica 2Health News:Aspreva receives final court approval for acquisition by Galenica 3Health News:Aspreva receives final court approval for acquisition by Galenica 4
... Medic 6 Defibrillator is a simple ... response that is compact with a ... portable at only 13.5 lbs. It ... 360 joules,It has full summary pre- ...
Incontinence Pessaries...
HODGE with support designed for patient with limited pubic notch and mild cystocele. The folding HODGE Pessary with Support is indicated for the woman with stress urinary incontinence with a mild cyc...
... Incontinence Ring Pessary is ... with urinary stress incontinence. ... continence by stabilizing the ... active enhancement of urethral ...
Medicine Products: